Collin Collins
Chief Scientific Officer (CSO) at Hexamer Therapeutics
Vancouver, British Columbia, Canada
Find your path to Collin
316 people in our graph share verified history with Collin — schools, employers, funds. One of them is your warm intro.
Francisco GimenezunlockedCollin: together at UCSF (2008–2009)
×2Collin: together at UCSF
×7Collin: together at Lawrence Berkeley National Laboratory
Collin: together at University of British Columbia
About
Collin Collins is a Professor in the Department of Urologic Sciences at the University of British Columbia and a senior scientist and Director of the Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, with adjunct appointments at the University of California San Francisco Comprehensive Cancer Center and Fudan University in Shanghai. His work focuses on translational genomics, and he invented and patented End Sequence Profiling, a method for characterizing tumor genome structure and detecting fusion genes. Collins has authored over 80 peer-reviewed manuscripts, holds multiple patents, and serves on several scientific advisory and editorial boards, including those of the International Drug Discovery Science and Technology Conference and the Open Pathology Journal.
Chief Scientific Officer (CSO) at Hexamer Therapeutics
Experience
- Prostate Cancer Foundation China CommitteeMembercurrent2012 — present
- The Nicholas Connor InstituteScientific Advisory Boardcurrent2012 — presentGreater San Diego Area
- San Francisco State UniversityAdvisory Board Department Of Biological Sciencescurrent2011 — present
- BMC Cancer JournalEditorial Boardcurrent2010 — present
- Vancouver Prostate CenterProfessor Department of Urologic Sciences University of British Columbiacurrent2009 — present
- The Open Pathology JournalEditorial Advisory Boardcurrent2007 — present
- Combimatrix Molecular DiagnosticsScientific Advisory Board2009 — 2010
- Cambodian Future FundBoard Of Directors2008 — 2010
- UCSFAssociate Professor In Residence1998 — 2009
- Lawrence Berkeley National LaboratoryScientist1993 — 1998
- Lawrence Livermore National LaboratoryScientist1985 — 1988
Skills & more
Computer ScienceGenomics59Genetics43Molecular Biology28Life Sciences22Translational Research8Prostate Cancer7Lifesciences20Oncology9Cancer53Biotechnology10Bioinformatics18
+8 more
ScienceDNA sequencingCancer ResearchCellDrug DiscoveryComputational BiologyBiomarkersSequencingFrom Collin's professional profile.
Frequently asked questions
- Who is Collin Collins?
- Collin Collins is a Professor in the Department of Urologic Sciences at the University of British Columbia and a senior scientist and Director of the Laboratory for Advanced Genome Analysis at the Vancouver Prostate Centre, with adjunct appointments at the University of California San Francisco Comprehensive Cancer Center and Fudan University in Shanghai. His work focuses on translational genomics, and he invented and patented End Sequence Profiling, a method for characterizing tumor genome structure and detecting fusion genes. Collins has authored over 80 peer-reviewed manuscripts, holds multiple patents, and serves on several scientific advisory and editorial boards, including those of the International Drug Discovery Science and Technology Conference and the Open Pathology Journal.
- Where does Collin Collins work?
- Collin Collins is Chief Scientific Officer (CSO) at Hexamer Therapeutics.
- Where did Collin Collins go to school?
- Collin Collins studied at The University of British Columbia; San Francisco State University (Certificate, Genetic Engineering); Western New England University (BSc, Biology).
Same school
Also attended The University of British Columbia563
Joan MirallesHead of Administration & Valuation at Inveready Technology Investment GroupZack GrimmerInvestor at IVP (Institutional Venture Partners)Rares CrisanInvestor at Notable CapitalMarianne WuVenture Partner at Congruent VenturesBrendan BakerPartner at Rackhouse Venture Management LpAli KashaniVenture Partner at Think+ Ventures Management, Llc
+ 557 more
Also attended San Francisco State University155
Dana ChamorroVice President, Technology at Redpoint VenturesCiara Campbell BowenExecutive Assistant at Sapphire VenturesJulie WalkerInvestor at True VenturesEmily RabbittInvestor at True VenturesStephanie WatkinsOperations at 8VCIndra HusfeldOffice and Finance Coordinator at Sierra Ventures
+ 149 more
Also attended Western New England University9
Agathe BertrandSenior Associate, Wealth Management at Adams Street PartnersLarry DeroseFounder & CEO, AdvaStim, Inc. at AIFBill AmsbaughCTO and Partner at Cure VenturesNans RivatVice President at PACE Healthcare CapitalKevin EknaianSenior Vice President, Head of Global Institutional and Workplace Retirement Sales at American Century Private InvestmentsDanielle CarrManaging Director of Human Resources at Deerpath
+ 3 more
Shared employers
Also worked at San Francisco State University23
Breanna ManoreOperations at General PartnershipKarla MoraFounder & Managing Partner at Alante CapitalNancy HayesAngel Investor | Advisor to Women Entrepreneurs | Management Consultant | Executive CoachKelsey HayesExecutive Assistant at Knox LaneRaylin RondezExecutive Assistant at Acrew CapitalElena Diez CeciliaSenior Director, External Innovation, DPDS at Janssen R&D at Johnson & Johnson Innovation – JJDC
+ 17 more
Also worked at BMC Cancer Journal3
Also worked at UCSF180
Logan HilleLife Sciences Analyst at CincyTechPaul JennyBoard Chair at CincyTechFrancisco GimenezInvestment Team at 8VCUlrik B. NielsenGeneral Partner at Mission BiocapitalHani GoodarziFounder, Tahoe Therapeutics at Amplify PartnersCharles White, Ph.D.Principal at Illumina Ventures
+ 174 more
Also worked at Lawrence Berkeley National Laboratory132
Thomas WolfCo-founder & Chief Science Officer of Hugging FaceJessy RivestInvestor at Khosla VenturesBayan AlizadehPartner at S32Jan CrisostomoOperating Partner at Rackhouse Venture Management LpAvinash KantInvestor at Phoenix Venture PartnersDaphne ChePrincipal at Electric Feel Ventures Llc
+ 126 more